N@N

Nymox Pharmaceutical Corp (NASDAQ:NYMX), Down By 9.71% ($0.64) From $6.590 After BUYINS.NET Report Predicted Weakness Before Ea

^{Published on 2012-10-17 07:42:31 - WOPRAI}
 

October 17, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, October 5th 2012 stating that Nymox Pharmaceutical Corp (NASDAQ:NYMX) was expected to be Down Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=nymx&id=317440

At the time this story was written, Nymox Pharmaceutical Corp (NASDAQ:NYMX) is Down By 9.71% ($0.64) From $6.590 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Nymox Pharmaceutical Corp (NASDAQ:NYMX) - Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices in Canada, the United States, and Europe. The companys products include AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimers disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. Its products under development comprise NX-1207, which is in Phase III clinical trials for the treatment of benign prostatic hyperplasia; and NX-1207, which is ready for human clinical trials for the treatment of hepatocellular carcinoma and localized prostate cancer. The companys products in the preclinical stage comprise NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans; NXB-4221 for the treatment of difficult chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. It is also developing therapeutics for Alzheimers disease; drugs for the treatment of Alzheimers disease that target spherons; and therapeutic products for oncological indications, as well as holds various diagnostic markers and technologies, including a patented platform for point-of-care testing. Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Nymox Pharmaceutical Corp (NASDAQ:NYMX) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net